Now that the American Heart Association has issued its new guidelines, we need to carefully consider each woman's risk for coronary heart disease (CHD). Educating women today about their lifetime risk for CHD and working with every patient to implement the guidelines for CHD risk prevention may have a significant impact on women's health for the future.

Are women with polycystic ovary syndrome at increased risk of cardiovascular disease and, if so, what preventive measures need to be addressed?

An expert helps clinicians make sense of the screening intervals in the new guidelines for cervical cancer.

Most urinary tract infections in women are effectively treated with a short course of antimicrobial therapy. However, a number of patients—particularly those with recurrent, persistent, or complicated infections—present more challenging diagnostic and treatment situations. The authors offer a practical approach to managing both straightforward and complex cases based on a simple clinical classification scheme.

The position statement evaluates the risk-benefit ratio of perimenopausal and postmenopausal estrogen therapy and estrogen-progestogen therapy for treatment of menopause-related symptoms and disease prevention.

Perimenopause is now defined as the variable-length time frame during which menses become more erratic, and lasting through the 12 months of amenorrhea from the last menstrual period. This case-based approach offers several practical tips for managing this challenging time in your female patients.

Breaking the silence on ovarian cancer; Bad news for women with diabetes; News from the FDA

Once you discover microscopic hematuria, typically the next step is evaluation with a careful history and physical exam, then specific laboratory tests, and cystoscopic and radiologic studies.